Danish pharmaceutical giant Novo Nordisk is gearing up to introduce its blockbuster anti-diabetes and weight-loss drug Wegovy (semaglutide) in India. In a strategic move to gain an advantage over Eli Lilly’s newly launched Mounjaro (tirzepatide), Novo Nordisk has presented data showcasing Wegovy’s cardiovascular benefits in Indian patients, according to recent regulatory filings.
RBI likely sold $12 billion in gold reserves amid rupee pressure
India’s central bank, the Reserve Bank of India (RBI), is estimated to have sold nearly $12 billion worth of gold reserves within a two-week period ending May 22. The assessment, based on...





Discussion about this post